TrialPloS one2018

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.

Bancha Satirapoj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.